Compare Summit Therapeutics Inc (SMMT) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs United States Natural Gas Fund — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while United States Natural Gas Fund trades at $11.03 (market cap $517.27M). The key difference: Summit Therapeutics Inc is far larger — about 26.5× United States Natural Gas Fund's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and United States Natural Gas Fund for 22 Days on average.
| SMMT | UNG | |
|---|---|---|
Market Cap | $13.71B | $517.27M |
Volume | 6,173,057 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $26.38 | $16.90 |
52-Week Low | $12.43 | $9.63 |
Typical Hold Time | 16 Days | 22 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
UNG trades at $11.10, up 0.63% with a bullish technical signal from moving averages. The fund shows strong profitability with $65.15M net income for 2024, though revenue remains at $0.00. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy prices. The fund maintains a solid balance sheet with $594.68M in current assets and minimal liabilities.
Investment outlook remains cautiously optimistic given bullish technical indicators and strong profitability metrics. Key risks include natural gas price volatility and geopolitical factors affecting energy markets. The absence of traditional valuation metrics requires careful monitoring of underlying commodity trends for informed positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
